The FDA 505(b)(2) pathway is an accelerated pathway to get a New Drug Approval using data that was already previously submitted by other drug companies. It was designed to help you avoid unnecessary duplication of studies which have already been performed on a previously approved drug.
This idea can be used when you are:
You perform a bridging study to show bioequivalence to the approved drug asset and therefore can use their safety, non-clinical data and any other relevant data.
The time saving can be years – normal NDAs take 7-10 years whereas FDA 505(b)(2) can be under 2 years. The faster pathway to approval also creates cost saving efficiencies for you.